問卷

TPIDB > Search Result

Search Result

篩選

List

242Cases

2025-04-01 - 2032-12-31

Not yet recruiting
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung

  • Test Drug

    Capsules Intravenous infusion Intravenous infusion

Participate Sites
18Sites

Recruiting18Sites

2023-07-01 - 2026-09-30

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2023-10-01 - 2026-12-31

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Not yet recruiting3Sites

2024-02-01 - 2026-04-30

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Terminated5Sites

2024-03-01 - 2028-10-10

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2024-05-15 - 2030-12-31

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2024-06-01 - 2030-12-31

Phase II/III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2024-08-30 - 2028-03-31

Phase I

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2024-09-24 - 2029-12-31

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2024-11-29 - 2029-03-02

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites